ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study

Li, Jian; Zhang, Xinhua; Deng, Yanhong; Wu, Xin; Zheng, Zhichao; Zhou, Yongjian; Cai, Shirong; Zhang, Yanqiao; Zhang, Jun; Tao, Kaixiong; Cui, Yuehong; Cao, Hui; Shen, Kuntang; Yu, Jiren; Zhou, Ye; Ren, Wenxiao; Qu, Chenglin; Zhao, Wanqi; Hu, Jin; Wang, Wei; Yang, Jason; Shen, Lin*复旦大学; 北京大学; 华中科技大学; 上海交通大学; 哈尔滨医科大学; 浙江大学; 中山大学; 6; 1
ONCOLOGIST2023-2DOI: 10.1093/oncolo/oyac242
3被引21阅读
引用收藏
分享

摘要

Background Avapritinib is a type 1 kinase inhibitor designed to potently and selectively inhibit oncogenic KIT/PDGFRA mutants by targeting the kinase active conformation. This multicenter, single-arm, open-label, phase I/II bridging study of NAVIGATOR in Chinese patients evaluated the safety and the antineoplastic activity of avapritinib in Chinese patients with unresectable/metastatic gastrointestinal stromal tumors (GIST). Methods Phase I comprised dose escalation for safety and phase II dose determination. Phase II comprised dose expansion for safety/efficacy evaluations in patients with PDGFRA D842V mutations or patients having received at least 3 lines of therapy without PDGFRA D842V mutations. The primary endpoints were recommended phase II dose, safety, and Independent Radiology Review Committee (IRRC)-assessed objective response rate (ORR). Results No dose-limiting toxicities occurred (n = 10); the recommended phase II dose was avapritinib 300 mg once daily orally. Fifty-nine patients initially received avapritinib 300 mg. Common grade >= 3 treatment-related adverse events were anemia, decreased white blood cell count, increased blood bilirubin levels, and decreased neutrophil count. In patients with PDGFRA D842V mutations, IRRC- and investigator-assessed ORRs were 75% and 79%, respectively; clinical benefit rates were both 86%. Median duration of response/progression-free survival were not reached. IRCC- and investigator-assessed ORRs in patients in the fourth- or later-line setting were 22% and 35%, respectively. Median progression-free survivals were 5.6 months for both. Overall survival data were immature and not calculated. Conclusion Avapritinib was generally well tolerated and showed marked anti-tumor activity in Chinese patients with GIST bearing PDGFRA D842V mutations and notable efficacy as fourth- or later-line monotherapy (ClinicalTrials.gov Identifier: NCT04254939). @@@ This article evaluates the safety and the antineoplastic activity of avapritinib in Chinese patients with unresectable/metastatic gastrointestinal stromal tumors.

学科与关键词

关键词
tyrosine kinase inhibitoravapritinibgastrointestinal stromal tumorsPDGFRA D842Vfourth-line therapy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
ONCOLOGIST
发表日期
2023-02
卷期
第 28 卷, 第 2 期
页码
187-+
DOI
10.1093/oncolo/oyac242
语言
ENGLISH
成果收录
SCIE
资助标注
CStone Pharmaceuticals, Suzhou, China; Blueprint Medicines Corporation

作者

  • L

    Li, Jian (第一作者)

    2 · beijing canc hosp & inst · peking univ

  • Z

    Zhang, Xinhua

    1 · sun yat sen univ

查看全部 22 位作者收起作者
  • D

    Deng, Yanhong

    6 · sun yat sen univ

  • W

    Wu, Xin

    chinese peoples liberat army gen hosp

  • Z

    Zheng, Zhichao

    liaoning canc hosp & inst

  • Z

    Zhou, Yongjian

    fujian med univ

  • C

    Cai, Shirong

    1 · sun yat sen univ

  • Z

    Zhang, Yanqiao

    harbin med univ

  • Z

    Zhang, Jun

    1 · chongqing med univ

  • T

    Tao, Kaixiong

    huazhong univ sci & technol

  • C

    Cui, Yuehong

    fudan univ

  • C

    Cao, Hui

    shanghai jiao tong univ

  • S

    Shen, Kuntang

    fudan univ

  • Y

    Yu, Jiren

    1 · zhejiang univ

  • Z

    Zhou, Ye

    fudan univ

  • R

    Ren, Wenxiao

  • Q

    Qu, Chenglin

  • Z

    Zhao, Wanqi

  • H

    Hu, Jin

  • W

    Wang, Wei

  • Y

    Yang, Jason

  • S

    Shen, Lin (通讯)

    2 · beijing canc hosp & inst · peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417